ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters. Issue 1 (17th May 2016)

• Record Type: Journal Article
• Authors: Uettwiller, F; Sarrabay, G; Rodero, M P; Rice, G I; Lagrue, E; Marot, Y; Deiva, K; Touitou, I; Crow, Y J; Quartier, P
• Is Part Of: RMD open. Volume 2:Issue 1(2016)
• Publication Date: 2016-05-17
• Subjects: Systemic vasculitis -- Fever Syndromes -- Inflammation; Musculoskeletal system -- Diseases -- Periodicals; Rheumatism -- Periodicals; 616.7005
• DOI: 10.1136/rmdopen-2015-000236
• Languages: English
• ISSNs: 2056-5933

Abstract

Abstract : The objective of this paper is to: describe the phenotype compound heterozygote for mutations in CECR1 in two children. We describe the clinical and immunological phenotype, including the assessment of ADA2 activity, cytokine expression, interferon-stimulated and neutrophil-stimulated gene signatures, and the results of CECR1 sequencing. The first patient presented with intermittent fever, cutaneous vasculitis, myalgia and muscle inflammation on MRI leading to a provisional diagnosis of periarteritis nodosa. Subsequently, two cerebral lacunar lesions were identified following a brain stroke. Clinical features improved on anti-tumour necrosis factor therapy. The first patient's sister demonstrated early-onset, long-lasting anaemia with mild biological inflammation; at the ages of 3 and 5 years, she had presented 2 acute, transient neurological events with lacunar lesions on MRI. CECR1 sequencing identified both sisters to be compound heterozygous for a p.Tyr453Cys mutation and a previously undescribed deletion of exon 7. ADA2 activity was reduced by 50%. Neutrophil-stimulated genes were not overexpressed, but interferon-stimulated genes were. The expression of a panel of other cytokine transcripts was not significantly altered. In conclusion, searching for CECR1 mutation or assessing ADA2 activity should be considered in patients with an atypical presentation of inflammatory disease.